Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States.
- Sector(s): Healthcare
- Industry: Biotechnology
- Full Time Employees: 41
- Founded in 2013
- Headquartered in Cambridge, Massachusetts.
- https://sperotherapeutics.com
Spero Therapeutics (NASDAQ:SPRO) priced its initial public offering to the low end of its range, at $14.
It had marketed at $14-$16/share.
It offered 5.5M common shares at that price, for a raise of $77M.
Shares opened at $13.25, ~5% lower than the offer price of $14.
